{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:18:28Z","timestamp":1794129508389,"version":"4.8.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title\/><jats:p>As the use of immune checkpoint inhibitors for several different malignancies becomes more mainstream, their side-effect profile raises new challenges. In 2011, the Food and Drug Administration approved the first checkpoint inhibitor for the treatment of advanced melanoma, and since then, checkpoint inhibitors have demonstrated efficacy in many other tumor types. Given the frequent use of immune checkpoint inhibitors in a wide range of cancers today, the diagnosis and management of their immune-mediated toxicities need special attention. One of the most common is immune-mediated colitis. Workup and management of immune-mediated colitis can be challenging and is the purpose of this review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key Points<\/jats:title><jats:p>Rate of immune mediated colitis differ from different kind of immune checkpoint inhibitor treatment. To work up immune-mediated colitis, tests to rule out infectious etiologies of diarrhea, colonoscopy and abdominal image will help to differentiate immune mediated colitis from colitis from other etiology. Patients with mild colitis can be managed with supportive therapies alone, but more severe cases may require immunomodulators such as steroid. Refractory cases may require tumor necrosis factor (TNF) inhibitors, such as infliximab in addition to steroid treatment.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0304","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T19:15:13Z","timestamp":1567797313000},"page":"197-202","source":"Crossref","is-referenced-by-count":22,"title":["Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors"],"prefix":"10.1093","volume":"25","author":[{"given":"Bhavana Pendurthi","family":"Singh","sequence":"first","affiliation":[{"name":"Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwu Ruth","family":"He","sequence":"additional","affiliation":[{"name":"Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"2021122510131693000_R1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"2021122510131693000_R2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"2021122510131693000_R3","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","article-title":"CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996;184:301]","volume":"183","author":"Walunas","year":"1996","journal-title":"J Exp Med"},{"key":"2021122510131693000_R4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"2021122510131693000_R5","volume-title":"Targeted Therapies in Cancer","author":"Lacroix","year":"2014"},{"key":"2021122510131693000_R6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J Exp Med"},{"key":"2021122510131693000_R7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"2021122510131693000_R8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fonc.2017.00056","article-title":"Incidence of immune-related adverse events with program death receptor-1 and program death receptor-1 ligand-directed therapies in genitourinary cancers","volume":"7","author":"Maughan","year":"2017","journal-title":"Front Oncol"},{"key":"2021122510131693000_R9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.12788\/jhm.2925","article-title":"Immunotherapy-induced colitis: An emerging problem for the hospitalist","volume":"13","author":"Marin-Acevedo","year":"2018","journal-title":"J Hosp Med"},{"key":"2021122510131693000_R10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"2021122510131693000_R11","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122510131693000_R12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122510131693000_R13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122510131693000_R14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122510131693000_R15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122510131693000_R16","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122510131693000_R17","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 Study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122510131693000_R18","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2021122510131693000_R19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/cbr.2008.0607","article-title":"Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis","volume":"24","author":"Minor","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"2021122510131693000_R20","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/j.cgh.2016.09.017","article-title":"Nivolumab-induced colitis treated by infliximab","volume":"15","author":"Yanai","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122510131693000_R21","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000278","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management","volume":"3","author":"Geukes Foppen","year":"2018","journal-title":"ESMO Open"},{"key":"2021122510131693000_R22","first-page":"857519","article-title":"Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: The underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"2021122510131693000_R23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.192.2.295","article-title":"Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation","volume":"192","author":"Read","year":"2000","journal-title":"J Exp Med"},{"key":"2021122510131693000_R24","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/ecco-jcc\/jjx081","article-title":"Colon immune-related adverse events: Anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities","volume":"11","author":"Coutzac","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2021122510131693000_R25","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122510131693000_R26","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/sj.bmt.1704474","article-title":"Enteral metronidazole for the prevention of graft versus host disease in pediatric marrow transplant recipients: Results of a pilot study","volume":"33","author":"Guthery","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"2021122510131693000_R27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2021122510131693000_R28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coph.2010.01.005","article-title":"Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases","volume":"10","author":"Taylor","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"2021122510131693000_R29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1060028014528152","article-title":"Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient","volume":"48","author":"Merrill","year":"2014","journal-title":"Ann Pharmacother"},{"key":"2021122510131693000_R30","first-page":"149","article-title":"Cause for controversy? Infliximab in the treatment of ulcerative colitis: An update","volume":"2","author":"Lawlor","year":"2009","journal-title":"Clin Exp Gastroenterol"},{"key":"2021122510131693000_R31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/1568010033484296","article-title":"IL-6 and Crohn's disease","volume":"2","author":"Ito","year":"2003","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"2021122510131693000_R32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14728222.8.4.287","article-title":"Novel therapy for Crohn's disease targeting IL-6 signalling","volume":"8","author":"Ito","year":"2004","journal-title":"Expert Opin Ther Targets."},{"key":"2021122510131693000_R33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2021122510131693000_R34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis","volume":"66","author":"Bergqvist","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"2021122510131693000_R35","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122510131693000_R36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CMR.0000000000000165","article-title":"Ipilimumab-induced colitis in patients with metastatic melanoma","volume":"25","author":"De Felice","year":"2015","journal-title":"Melanoma Res"},{"key":"2021122510131693000_R37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2021122510131693000_R38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-017-0495-4","article-title":"Immune checkpoint inhibitor-induced colitis: Diagnosis and management","volume":"12","author":"Prieux-Klotz","year":"2017","journal-title":"Target Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0304","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/3\/197\/41919530\/oncolo_25_3_197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/3\/197\/41919530\/oncolo_25_3_197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T20:06:34Z","timestamp":1664309194000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/3\/197\/6443457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9,6]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0304","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,1]]},"published":{"date-parts":[[2019,9,6]]}}}